The Effect of Oral Contraceptives on Women Balance

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

1. Recording Data Sheet:

All data and information of each woman in both groups (A & B) participated in this study were recorded in a recording data sheet (Appendix II).

2. Weight-Height scale:

A valid and reliable weight -height scale, with a range of 1 to 150 kilograms weight, and 1 to 200 centimeters height was used to measure the relevant subject's data.

3. Siemens Immulite Immunoassay System:

(Siemens Medical Solutions Diagnostics Immulite 1000,Los Angles, CA, 900-456900 U.S.A) to measure the serum Progesterone and Estradiol levels in both groups (A& B) using (TKE 21 Kit) for Estradiol and (TKPG 1 Kit) for Progesterone.

4. Biodex balance system:

Biodex Balance System (BBS), P.O. Box 702, Shirley, Ny 11967.It is an apparatus used to measure the dynamic balance. It utilizes dynamic multi axial platform. This platform allows approximately 20 degree inclination in 360 degree range and is interfaced with computer software. It measures the patient's ability to control the platform's angle of tilt, which is quantified as a variance from the center, as well as the degree of deflection over time at various stability levels as shown in (Fig. 6).

Stability levels allowed by the system ranged from one to eight. Stability level 8, allows the highest level of stability as it makes the platform to be the least tilted. On the other hand, stability level one represents the least level of stability and is more difficult for the subject to maintain stability on.

The test consists of recording the patient's ability to control the platform variance from a perfectly balanced position. A large variance is indicative of poor control and balance. Further definition is realized with the quantification of Anterior/ Posterior and Medial/Lateral responses.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cairo University
• Treatments: Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Drospirenone

Criteria

Inclusion Criteria:

• All women in group (A) had takenthe oral contraceptive pill have done so routinely for the past three months.

• All women in group (B) had a normal menstrual cycle; use any other non-hormonal contraceptive method.

• Their body mass index did not exceed 30 Kg/m2.

• All women had a normal menstrual cycle of 25-32 days for the past 3 months.

• They can stand independently.

Exclusion Criteria:

• Respiratory or heart problems.

• Skeletal deformityorusing assistive devices.

• Visual and vestibular system affection.

• Cognition problems.

• Previous surgeries at their back and/or lower limbs.

• Genital and breast cancer and active liver disease.